AstraZeneca
AZN
669 hedge funds and large institutions have $22.7B invested in AstraZeneca in 2020 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 216 increasing their positions, 209 reducing their positions, and 48 closing their positions.
163% more call options, than puts
Call options by funds: $349M | Put options by funds: $133M
140% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 48
15% more capital invested
Capital invested by funds: $19.8B → $22.7B (+$2.92B)
11% more funds holding
Funds holding: 603 → 669 (+66)
3% more repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 209
0.54% less ownership
Funds ownership: 16.85% → 16.31% (-0.54%)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$137M |
| 2 |
Morgan Stanley
New York
|
+$78.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$78.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$64.7M |
| 5 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$64.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$662M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$574M |
| 3 |
Primecap Management
Pasadena,
California
|
-$154M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$43.8M |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$31.4M |
AZN Hedge Fund Activity: Q2 2020 in Review
669 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2020, worth a combined $22.7B — up 15% from $19.8B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new AZN positions and 48 closed out — a net gain of 67 holders — while 216 added to existing stakes and 209 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $137M. The largest seller was Wellington Management Group, cutting an estimated $662M.
- 669 institutional investors held AstraZeneca (AZN) as of Q2 2020, up from 603 in Q1 2020.
- Funds reported $22.7B of AstraZeneca stock for Q2 2020, up 15% quarter-over-quarter.
- 115 funds opened new AstraZeneca positions in Q2 2020 and 48 closed out, a net change of +67 holders.
- The largest AstraZeneca buyer in Q2 2020 was Arrowstreet Capital, an estimated $137M added.
- The largest AstraZeneca seller in Q2 2020 was Wellington Management Group, an estimated $662M sold.
Based on aggregated 13F filings for Q2 2020.